30 OctExcept for the historical information herein.

Except for the historical information herein, this news release this news release are forward-looking statements that involve a number of risks and uncertainties. Actual results may vary substantially on a number of factors , which are described in SkyePharma 20-F and other documents on file with the SEC. These include without limitation risks in obtaining and renewing approval for existing, new or expanded indications for its products, other regulatory risks, risks related to SkyePharma ability pharmaceutical products in a large scale, risks that customer inventory will be greater than previously thought, Risks related to SkyePharma to integrate the ability to manage growth, market a pharmaceutical product on a large scale and and manage an internal sales and marketing organization and maintain or expand sales and market share for its products, associated with the associated with the ability, regulatory compliance, to ensure risks associated with the research, development and approval of new pharmaceutical products, risks associated with research and development and skills, the market acceptance of and continued demand for SkyePharma products and the impact of increased competition risks associated with expected sales and earnings growth and the possibility that potential will not be achieved, competitive products and pricing, and risks associated with the ownership and use of intellectual property rights connected..

Photonic stimulation is like ‘Star Trek ‘medicine – sounds like something from the future, the far-fetched to have in today’s world it. However, quantum healing with near infrared light photons today. Reality and is ready for mainstream in medical practice This powerful, effective, safe and cost-effective technology revolutionized medical treatment of pain, many neurological disorders, and a variety of musculoskeletal and soft tissue diseases. Many health problems that previously notoriously difficult or even impossible successfully manage successfully manage now benefit from photonic stimulation.Multicentre today announced Enrollment has completely for the largest atrial fibrillation outcomes trial The RE-LY survey.

The RE-LY study compares two blinded doses with oral dabigatran etexilate Dabigatran by warfarin in patients with previously atrial fibrillation of at moderately severe to high level of risk of stroke. Over 150,000 the standard treatment be to avoid stroke in these patients the vitamin K antagonists warfarin. Has that warfarin be currently prescribed for merely half of eligible patients. ,, Professor to the epidemiology cardiac and leader of the study coordination center at McMaster University Hamilton, said: ‘Patient recruitment into RE-LY has exceeded our original expectations is far. ‘.